Non-coding RNA GAS5 (growth arrest-specific transcript 5) is a 5 -TOP (5 -terminal oligopyrimidine tract) RNA, whose translation, and consequently also stability, is controlled by the mTOR (mammalian target of rapamycin) pathway. GAS5 was identified by functional expression cloning and is necessary and sufficient for normal growth arrest in both leukaemic and untransformed human T-lymphocytes. GAS5 is also required for the inhibitory effects of rapamycin and its analogues on T-cells. The striking functional effects of GAS5 may be mediated through the snoRNAs (small nucleolar RNAs) encoded in its introns and/or through the unusual folding of the mRNA itself, which sequesters, and therefore inhibits, the glucocorticoid receptor.
Introduction: the identification of GAS5 (growth arrest-specific transcript 5)
The control of cell proliferation and survival is crucial to human physiology and pathology. This is particularly important for lymphocytes, since the regulation of these cells at the individual level is essential, both for producing and controlling the adaptive immune response, and for selftolerance which is an essential property of a healthy immune system.
A logical consequence of the importance of these controls in healthy individuals is that defects in these systems underlie many disease processes, from autoimmune disease to cancer [1, 2] . The pharmaceutical manipulation of these processes, e.g. by inhibition of the crucial protein kinase mTOR (mammalian target of rapamycin), is critically important for immunosuppression [3] , as well as for leukaemia therapy [4] . Although investigations into the regulation of cell proliferation have been carried out over several decades, comparably extensive investigations into the molecular mechanisms controlling cell death are more recent [5, 6] . These investigations have shown that the mechanisms regulating both processes are very complex, and that there are many indications that critical elements are yet to be discovered [7] [8] [9] [10] .
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forward genetics [11] provides a complementary strategy with the important advantage that it is entirely independent of previously established knowledge. In addition, this approach identifies genes playing causal roles in the cell death process, and distinguishes this crucial group of genes from those which, while being differentially expressed, do not affect the cell death/survival decision [10] . This in-built focus on genes that play causal roles inevitably identifies those most likely to be of real importance, both biologically and medically. Twenty-two candidate apoptosis regulators have been identified in this way [12] and, in addition to GAS5 (see below), six of them have been confirmed as regulators of lymphoid and/or myeloid apoptosis {i.e. LUCA-15/RBM5 [13] [14] [15] [16] , protein phosphatase 4 [17] [18] [19] , v-ATPase E (vacuolar ATPase E) [20] , Fau [21] [22] [23] , RACK1 (receptor for activated C-kinase 1) [24] and PLAC8/Onzin [12] }.
The functional expression cloning strategy resulted in the identification of GAS5 [12] , originally isolated by Schneider et al. [25] , from a subtraction cDNA library identifying genes enriched on growth arrest. GAS5 is encoded at 1q25, an important locus for the development of the autoimmune disease SLE (systemic lupus erythematosus [26] [27] [28] ). GAS5 itself has been identified as an SLE-susceptibility gene in a mouse model system [29] . Several types of leukaemia and lymphoma display abnormalities in 1q25 [30, 31] . GAS5 is involved in a chromosomal rearrangement with Notch 1 in radiation-induced thymic lymphoma [32] , and is upregulated 3.3-fold (the greatest up-regulation for any gene in the whole-genome array) by oncogenic kinases associated with myeloproliferative disorders [33] .
GAS5 encodes snoRNAs (small nucleolar RNAs) in its introns, and its exons contain a small ORF (open reading frame) that does not encode a functional protein [34] ; other mammalian snoRNAs are also encoded in the introns of genes coding for non-functional proteins [35] . GAS5 is a 5 -TOP (5 -terminal oligopyrimidine tract) RNA, i.e. it has a TOP sequence at its 5 -end. This motif is shared by a hundred or so different mRNAs encoding ribosomal proteins, translation initiation factors and other proteins involved in protein synthesis. The translation of 5 -TOP RNAs is controlled at least in part by the mTOR pathway [36] , and this may explain the influence of the mTOR pathway on GAS5 levels [37] . Since the GAS5 transcript contains a stop codon in an early exon, when cells are actively growing and all 5 -TOP RNAs are being actively translated, GAS5 transcripts are rapidly degraded by nonsense-mediated decay. When the translation of 5 -TOP transcripts is reduced in growth arrested or rapamycin-treated cells, nonsense-mediated decay no longer occurs and GAS5 transcript levels increase [37] , consistent with its original designation as a growth-arrestspecific transcript [25] .
The role of GAS5 in T-cell growth arrest
The isolation of a W7.2 mouse thymoma clone that was resistant to a normally lethal dose of gamma radiation, and which contained a fragment of GAS5 sequence [12] , was the first indication that modulation of GAS5 expression levels could provide resistance to apoptosis. The GAS5 transcript gives rise to many different splice variants, and the expression of several, but not all, of these, produced growth arrest and some induction of apoptosis in the leukaemic T-cell line CEM-C7 [38] . This indicated that GAS5 may be playing an active role in growth arrest, rather than simply being passively associated with growth arrest. However, overexpression studies may sometimes result in artefacts that have little physiological relevance. For this reason, endogenous GAS5 expressed in the CEM-C7 leukaemic T-cells was down-regulated using three different GAS5 siRNAs (small interfering RNAs). Although this produced little discernible effect on the exponential phase of cell growth, the growth arrest that occurred in control cells was markedly inhibited by down-regulation of GAS5 by siRNAs (Figure 1 ). This indicated that endogenously expressed GAS5 was required for normal growth arrest in this leukaemic T-cell line. It is interesting to note that this experiment clearly demonstrates that the growth arrest normally occurring in T-cell cultures cannot be simply the result of complete exhaustion of nutrients, since the GAS5 siRNA-treated cultures continue to grow above the density of control cultures. Growth arrest in control cultures, therefore, is a signal-mediated event, and this signal, leading to growth arrest, requires GAS5. Down-regulation of GAS5 also protected CEM-C7 T-cells from the loss of colonyforming ability produced by 3-days serum withdrawal or dexamethasone treatment [38] .
Overexpression and down-regulation of GAS5 produced similar effects on primary cultures of proliferating human Tlymphocytes, that is, on untransformed human T-cells [38] . GAS5 expression is therefore necessary and sufficient for normal growth arrest in human T-cells, suggesting that it may be of considerable biological and clinical importance. Reproduced from Mourtada-Maarabouni et al. [38] with permission.
The role of GAS5 in the inhibitory effects of rapamycin on human T-cells
Since the mTOR protein kinase plays a pivotal role in the control of cell growth and proliferation, and the GAS5 transcript is a 5 -TOP RNA whose translation is known to be controlled, at least in part, by the mTOR pathway, the potential involvement of GAS5 in the inhibitory effects of mTOR inhibitors, such as rapamycin, has been investigated [39] . Down-regulation of endogenous GAS5 levels by siRNAs (as above) substantially reduced the inhibitory effects of rapamycin and its analogues (rapalogues) on both leukaemic and untransformed human T-cells. GAS5 siRNAs reduced the inhibitory effects of rapamycin, as measured by BrdU (bromodeoxyuridine) incorporation, Ki67 immunostaining, direct counting of viable cell number and propidium iodide staining followed by FACS analysis. Dependence on GAS5 was also demonstrated for the clinically important rapamycin analogues temsirolimus and everolimus [39] . Figure 2 shows the alleviation of the inhibitory effects of temsirolimus and everolimus by three different GAS5 siRNAs, as monitored by BrdU incorporation.
Alleviation of inhibitory effects by GAS5 siRNAs was substantial both for leukaemic and untransformed T-cells, being approx. 50 % or more [39] . The true magnitude of the protective effect is likely to be greater than those since the transfection efficiency for these experiments was between 65 % and 85 %, that is, 15-35 % of cells did not contain GAS5 siRNAs. Even allowing for this, the protective effect of GAS5 siRNAs is clearly incomplete, as would be expected given the complexity of the effects of mTOR activity and mTOR inhibition [40] . However, these observations demonstrate that most of the inhibitory effects of rapalogues on both untransformed and transformed human T-cells are mediated through GAS5.
Down-regulation of GAS5 produced a much smaller protective effect against the ATP-site mTOR inhibitor Torin 1 (M. Mourtada-Maarabouni and G.T. Williams, unpublished work). Since Torin 1 [41] and the other ATP-site inhibitors of mTOR antagonize a broader range of the effects of mTOR than rapamycin and its analogues, this observation is consistent with the requirement for GAS5 in signalling pathways specifically affected by the rapalogues. Inhibitory effects produced by the ATP-site mTOR inhibitors such as Torin 1 are very likely to include effects on pathways which do not require GAS5, so that the inhibitory effects of these compounds are much less affected by GAS5 siRNAs.
Molecular mechanisms which may account for the striking functional effects of GAS5
Since the largest ORF in GAS5 mRNA is small, poorly conserved, and unlikely to encode a functional protein, it has naturally been assumed that the important functional elements of the GAS5 gene are the snoRNAs encoded in its introns. The human GAS5 gene encodes 10 box C/D snoRNAs, which are predicted to act as guide RNAs for the methylation of specific residues in ribosomal RNA. This methylation is important for fine tuning rRNA function and has been thought of as essentially a housekeeping activity. However, U50, a separately encoded box C/D snoRNA, has recently been implicated in the development of both prostate cancer [42] and breast cancer [43] . snoRNA U50 has therefore been suggested to be a potential tumour suppressor gene, as a 2 bp deletion in U50 is associated with clinically significant prostate cancer [42] . In addition, overexpression of wild-type U50 in a prostate cancer cell line significantly reduced colonyforming efficiency [42] . These observations suggest that box C/D snoRNAs may play previously unsuspected roles in controlling cell fate.
A further very interesting and unexpected twist in the GAS5 story has recently been provided by Kino et al. [44] . This group showed that, although the mature spliced form of the GAS5 mRNA does not encode a functional protein, it nevertheless has important functional activity. This activity appears to derive from folding of the mRNA itself to form a mimic of the DNA-binding domain that normally interacts with the glucocorticoid receptor. GAS5 mRNA itself thus sequesters the glucocorticoid receptor and inhibits the glucocorticoid pathway. It is therefore through this very novel mechanism that GAS5 may produce some of its important functional effects. However, this cannot be the whole story, since it is difficult to account for the inhibition of dexamethasone-induced T-cell death by GAS5 siRNAs [38] by such a mechanism.
Evolution of GAS5
GAS5 appears to provide an important link, at least in T-cells, between the control of protein synthesis, and therefore cell growth, by the mTOR pathway, and the control of proliferation and cell survival. It is attractive to speculate that at some time in its evolutionary history the GAS5 gene, in common with most other 5 -TOP RNAs, encoded a functional protein, perhaps a ribosomal protein. Once the ORF encoding this protein became redundant through gene duplication, the appearance of an early stop codon through point mutation would not have had a deleterious effect on the cell. In addition, since the GAS5 transcript is protected from nonsense-mediated decay and accumulates on inhibition of translation, the acquisition of anti-proliferative and antisurvival signals by the GAS5 gene would immediately link inhibition of translation to inhibition of the cell cycle. The anti-proliferative and anti-survival signals provided by GAS5 may be mediated through an as yet poorly defined activity of the encoding snoRNAs, through the inhibition of steroid receptor pathways by the GAS5 mRNA itself, or through some combination of these effects (and possibly others too!).
Clinical relevance of the studies on GAS5
The unexpected observation that T-cell growth arrest and the inhibitory effects of rapamycin and its analogues are dependent on non-coding RNA GAS5 may have important clinical implications, because of the use of these compounds in immunosuppression and in cancer therapy. Down-regulation of GAS5 produces a much greater effect on the inhibition by rapalogues than on inhibition by the broader specificity inhibitor Torin 1. Further investigation and subsequent targeting of the GAS5 pathway may therefore allow greater specificity in immunosuppression and cancer therapy, eliminating or reducing unwanted side effects in both cases.
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